We have generated mouse transgenic lineages for C3G (tgC3G) and C3GΔCat (tgC3GΔCat, C3G mutant lacking the GEF domain), where the transgenes are expressed under the control of the megakaryocyte and platelet specific PF4 (platelet factor 4) gene promoter. Transgenic platelet activity has been analyzed through in vivo and in vitro approaches, including bleeding time, aggregation assays and flow cytometry. Both transgenes are expressed (RNA and protein) in purified platelets and megakaryocytes and do not modify the number of platelets in peripheral blood. Transgenic C3G animals showed bleeding times significantly shorter than control animals, while tgC3GΔCat mice presented a remarkable bleeding diathesis as compared to their control siblings. Accordingly, platelets from tgC3G mice showed stronger activation in response to platelet agonists such as thrombin, PMA, ADP or collagen than control platelets, while those from tgC3GΔCat animals had a lower response. In addition, we present data indicating that C3G is a mediator in the PKC pathway leading to Rap1 activation.
C3G transgenic mouse models with specific expression in platelets reveal a new role for C3G in platelet clotting through its GEF activity

Introduction
Rap1 is a small GTPase of the Ras family that is ubiquitously expressed [1] . Many studies support a role for the Rap1 isoform Rap1b (but not Rap1a) in critical aspects of platelet function, including aggregation, coagulation, adhesion and spreading, through the platelet integrin αIIbβ3 [2, 3] . Rap1b is highly expressed in mature megakaryocytes and platelets, accounting for about 0.1% of the total cellular proteins [3] . Recently, genetic evidences have demonstrated that Rap1b is involved in a common crucial step required for platelet activation [4] . Rap1b participates in the responses triggered by most platelet agonists, including ADP, collagen, epinephrine, thrombin and PMA [4] [5] [6] . In particular, ADP, thrombin and PMA activate platelet Rap1b through pathways involving an increase in intracellular calcium via also an essential activator of Rap1 during junction formation, both in epithelial and endothelial cells [17] . In addition, C3G has been implicated in Rap1-dependent adhesion in many hematopoietic-cell types [18, 19] . Based on the critical role of C3G in adhesion processes regulated by Rap1, we can hypothesize that C3G, which is expressed at low level in mouse platelets [20] , could participate in Rap1-mediated platelet functions. This is supported by previous data showing the involvement of C3G in thrombopoietin (TPO)-mediated Rap1 activation during megakaryocytic differentiation to platelets [3] . TPO binding to the MpI receptor induces CrkL phosphorylation and the recruitment of a Cbl/CrkL/C3G complex, which results in the sustained activation of ERKs [21] .
Rap1 is rapidly activated after stimulation of human platelets with α-thrombin.
Phospholipase C-mediated increase in intracellular calcium is necessary and sufficient for this activation, which suggests the participation of CalDAG-GEFs [5, 22] . Nevertheless, thrombin induces a second peak of Rap1 activation, which is mediated by protein kinase C (PKC), but independent of Ca 2+ and CalDAG-GEF [5, 14] . The specific components of this second pathway, and in particular, the specific GEF that contributes to the second wave of Rap1 activation has not been identified so far.
To examine whether C3G might play a role in platelet functions, we have generated C3G and C3GΔCat (C3G mutant with a deletion in the GEF domain) transgenic mice with specific protein over-expression in megakaryocytes and platelets. In vivo and in vitro experiments revealed a higher activation and aggregation of C3G transgenic platelets than those from wild type animals. In contrast, platelets expressing the C3GΔCat mutant showed impaired activation and aggregation. Thus, our results indicate that the manipulation of C3G expression modifies platelets response and therefore, it could play an important role as a therapeutical target in thrombotic disorders through the modulation of Rap1 activity.
Unexpectedly, C3G transgenic mice have a significant higher number of neutrophils than control mice, suggesting a possible C3G function in neutrophil development.
Platelet purification for RNA analysis
Blood (0.5-1 ml) was collected by retro-orbital bleeds from anesthetized mice (156 mg/kg ketamine, 6 mg/kg valium and 150 µg/kg atropine in 0.9% NaCl) and used to prepare platelet-rich plasma (PRP) upon treatment with 200-400 µl of acid citrate-dextrose (ACD)
anticoagulant solution (80 mM trisodium citrate, 52 mM citric acid, 180 mM glucose). The PRP was isolated by spinning the anticoagulated blood at 200 g, 20 min at RT. This PRP was centrifuged at 3160 g for 10 min to obtain the platelet pellet. Remaining red cells were eliminated by a brief incubation of the pellet with 1% ammonium oxalate. After two additional washes in PBS, the platelet pellet was resuspended in RLT lysis buffer from RNeasy kit (QIAGEN) following the manufacturer specifications for total RNA extraction.
Semiquantitative RT-PCR
cDNA from transgenic and control platelets was obtained from RNA using SuperScript® II Reverse Transcriptase (Invitrogen) and amplified by PCR to determine C3G expression using specific primers corresponding to different human C3G exons: Ex3 Forward (F): 5´-GCAACAGACAGATTTCTACCAG-3´; Ex4 Reverse (R): 5´-CTGTGCTGAATTCGAGGATC-3´; Ex5R: 5´-CTTCACTCCATCCAGCACA-3´; Ex7F: 5´-AGCAGAGCTCCCCCTGA-3´; Ex8F: 5´-CCTCCACCAGCATTGACAC-3´; Ex9R: 5´-CTAGTGTTTCACAGCTTGTGTT-3´; Ex10F: 5´-ACCACTATGATCCCGACTATG-3´;
Ex12R: 5´-TCACTGCCGTCTCTGCTG-3´; Ex15F: 5´-GATTTGGTGTTGTACTGCGAG-3´; Ex17R: 5´-CCTGGCTGCTACCCCC-3´; Ex22F: 5´-GGCCTGGCCGAGTACT-3´;
Ex24R: 5´-TGCTGGAAGCAGCGCATG-3´. The amplified fragments were normalized against the mouse gene CD41, a platelet specific internal control, using primers: mCD41-F1:
5'-ATGCGGGCTCTCAGCAACATTG-3' and mCD41-R1: 5'-TTGCCACAGGCAACATCACGAC-3'. The conditions for PCR were: 94°C, 45s; 55°C, 45s;
and 72°C, 80 min for 35 cycles. Densitometric analysis of the bands was performed using Image J (Image Processing and Analysis in Java) free software.
Megakaryocytic differentiation
Freshly isolated bone marrow cells from femurs of 6-8 week-old mice were cultured in RPMI supplemented with 20% horse serum and maintained at 5% CO 2 and 33 °C.
Megakaryocytes were differentiated from bone marrow cultures by addition of 50 ng/ml thrombopoietin (TPO, CellGenix) to promote megakaryopoiesis. After 7 days, cells in suspension were collected and used to prepare protein extracts or total RNA as described above. Total Rap1 present in platelet lysates was determined in a 20 µl of lysate sample, removed prior to bead addition, by Western-blot analysis of Rap1. Fold stimulation of active Rap1 was determined by densitometry using Image J free software.
Flow cytometric analysis of neutrophil content
The percentage of neutrophils in whole blood was determined by flow cytometry using antibodies against the granulocyte specific markers Ly-6G/6C (Gr1) and CD11b (Mac1) (BD Pharmingen 
Evaluation of blood cellularity
White blood cells and platelet counting was determined from EDTA-anticoagulated blood (30 µl) using a haemocytometer (Hemavet Counter HV950FS).
Statistical analysis
Data are represented as mean ± SEM. As comparisons were made between two experimental groups, an unpaired Student's t-test was used. Results were considered significant when p<0.05.
Results
Generation of transgenic mouse models expressing C3G or mutant C3GΔCat under the
PF4 gene promoter
C3G and C3GΔCat mutant (lacking the last 439 bp of full-length C3G catalytic domain) [23] , were cloned into plasmid PF4-Globin to specifically direct transgene expression to megakaryocytes and platelets [24, 25, 31] . To do so, the fragment carrying the β-globin gene was replaced by C3G-or C3GΔCat-fragments. A LoxP-PGK-Neo-LoxP cassette was also inserted in both constructs. The resulting plasmids were named PF4-C3G-LN and PF4-C3GΔCat-LN, respectively ( Fig. S1 ), where the transgenes were under the control of the PF4 gene promoter (Fig. 1A, B) . The constructs also contain a Kozak consensus sequence to ensure a correct initiation of translation (Fig. 1A) . Both constructs were used to generate transgenic mice through blastocyst injection of stable ESC´s (performed by GenOway
Company, Lyon, France). We selected two C3G transgenic lines (2C1 and 6A6) and one C3GΔCat line (8A3), with correct integration of the transgenes (Fig. 1C, D ).
Characterization of C3G transgene expression
Semiquantitative RT-PCR analysis of total RNA from purified platelets, using primers for different C3G exons, revealed a significant C3G over-expression in transgenic platelets as compared to those from wild type mice ( Fig. 2A) . Platelets from heterozygous animals also showed a clear increase in C3G expression ( Fig. 2A ). An evident C3G over-expression (∼2-4 fold increase) was also detected in platelets from C3GΔCat transgenic animals. As expected, we did not observe any increase in the expression of exons 22-24 in C3GΔCat mutant, as this region was deleted (Fig. 2B ). Platelet specific CD41 gene (GPIIb, encoding the αIIb subunit of platelet integrin αIIbβ3) was amplified as a control of platelet integrity and loading. C3G
over-expression was also observed in TPO-differentiated megakaryocytes from the transgenic C3G-2C1 line ( Fig. 2C ), but no C3G over-expression was detected in other tissues such as liver or kidney ( Fig. S2 ), in agreement with the restricted expression of the transgenes to megakaryocytes and platelets [24] .
Expression of C3G and C3GΔCat transgenic proteins was evident in lysates of TPOdifferentiated megakaryocytes, as compared to wild type mice (Fig. 2D ). Transgene expression was also detected in platelets by flow cytometry (cells positive for CD41 and C3G-Cy5), although expression levels showed great variability among individuals (Fig. 2E, F ).
C3G and C3GΔCat transgenes alter the hemostatic function of platelets
To study the involvement of C3G on hemostasis, we performed tail-bleed assays in transgenic mice and their wild type siblings at weaning and 6 months later in the same animals. At weaning, tgC3G animals showed statistically significant shorter bleeding times than control animals (mean ± SEM: 44.0 ± 4.5 seconds vs 64.2 ± 6.7 seconds, respectively, p=0.024). In contrast, the mean time for bleeding cessation in tgC3GΔCat animals was significantly higher than in their corresponding sibling controls (125.8 ± 17.7 seconds vs 86.8 was not due to defects in platelet formation, as the platelet number was similar in mice of the different genotypes (Table 1) . Additionally, there were no significant changes in hematocrit and hemoglobin levels in transgenic animals (Table S1 ), which means that C3GΔCat transgenic animals do not suffer from spontaneous hemorrhaging or anemia. These results indicate that C3G participates in platelet clotting through a mechanism dependent on its catalytic domain, which might involve the participation of Rap1 in this effect.
C3G and C3GΔCat transgenes modify the response of platelets to agonists
To determine whether the hemostatic defects observed in the transgenic animals were caused by impaired platelet function, we induced platelet activation by using several agonists known to activate Rap1, including thrombin, PMA and ADP. We determined P-selectin expression on the surface, as a measure of agonist-induced degranulation, and integrin αIIbβ3 activation, as a measure of inside-out signaling. As shown in Figure 4A , platelets from transgenic C3G mice showed higher expression of P-selectin on the surface in response to thrombin and PMA, while a significant reduced response to these agonists was observed in platelets from C3GΔCat transgenic animals as compared to wild type platelets. Similarly, platelets from C3G transgenic mice showed higher αIIbβ3 binding to Alexa Fluor® 488-conjugated fibrinogen in response to thrombin and ADP, while integrin from C3GΔCat-expressing platelets was less responsive to these agonists than control platelets (Fig. 4B) .
Similar results were obtained with the JON/A antibody regarding thrombin activation (data not shown). Expression of αIIbβ3 was similar in transgenic and control platelets, as assessed by flow cytometry with anti-CD41-APC (data not shown). Under our experimental conditions, PMA barely stimulated αIIbβ3 integrin, while ADP hardly affected surface P-selectin levels, as previously observed by other authors [28] . Additionally, platelet aggregation was impaired in tgC3GΔCat platelets in response to 5 µg/ml collagen. In contrast, tgC3G platelets showed increased aggregation as compared with platelets from wild-type mice (Fig. 4C, D) . Similar results were obtained in response to ADP, PMA and PAR4 peptide ( Fig. 4E and Fig. S3 ). All these in vitro experiments are in agreement with the tail-bleed assay and suggest that C3G
participates in PMA, thrombin, ADP and collagen-mediated platelet activation, possibly through Rap1. Moreover, fibrinogen-binding and aggregation assays indicate that C3G plays a role in the inside-out activation of αIIbβ3 integrin.
Activation of Rap1 in the transgenic platelets: Rap1 mediates the effect of C3G
All the above results indicate that C3G overexpression enhances Rap1-mediated integrin activation. In contrast, C3GΔCat transgene would behave as a C3G dominant negative mutant, inhibiting Rap1. To confirm this hypothesis, we performed a Rap1 activation assay on freshly isolated PRP stimulated with 0.2 U/ml α-thrombin for 1 min, conditions that have been widely validated [5, 12] . Basal Rap1 activation was increased in tgC3G mice as compared to wild type siblings, while tgC3GΔCat platelets showed lower Rap1-GTP basal levels than control animals ( Fig. 5A) . Similarly, Rap1 activation by thrombin was stronger in tgC3G platelets than in wild type platelets, while thrombin-stimulated tgC3GΔCat platelets showed lower Rap1-GTP levels than wild type siblings, in agreement with data in Figure 4 .
It has been described that, under aggregating conditions, thrombin-induced Rap1 activation is rapidly downregulated [5] . When the experiment was performed under these conditions (platelets stirred during incubation), we observed a faster Rap1 downregulation in tgC3G platelets and a significant lower dowregulation in tgC3GΔCat platelets as compared to their respective controls (Fig. 5B ). All these results indicate that transgenic C3G and C3GΔCat expression upregulates or downregulates Rap1 activation, respectively, which is in agreement with their effects in platelet aggregation.
C3G is a relevant mediator in the PKC pathway leading to Rap1 activation
Platelet aggregation stimulated by PMA was not affected in CalDAG-GEF1 KO platelets [12] , which suggests the existence of other Rap1 GEFs playing a role in PKCmediated Rap1 activation. To assess whether C3G could contribute to the PKC-Rap1 pathway in platelets, we performed a Rap1 assay on PRP stimulated with 0.2 µM PMA for 5 min in the presence or absence of the PKC inhibitor bisindolylmaleimide. Results in Figure 6A show that, PMA stimulates Rap1, in agreement with previous reports [5] . This stimulation was much higher in C3G transgenic platelets than in wild type platelets, which is in agreement with the results shown in Figure 4 and suggests that C3G participates in the platelet PKC pathway.
Furthermore, the increase in PMA-induced Rap1 activation observed in C3G transgenic platelets was almost completely abolished by bisindolylmaleimide, which indicates that PKCinduced Rap1 activation is mediated by C3G. This was confirmed by the absence of Rap1 activation in response to PMA in tgC3GΔCat platelets. These results are supported by platelet activation assays monitoring P-selectin expression on the surface. Figure 6B shows that the increase in P-selectin expression observed in C3G transgenic platelets stimulated with PMA was prevented upon pretreatment with bisindolylmaleimide. In contrast, plateletet activation by thrombin was only partially inhibited by bisindolylmaleimide (Fig. 6B ), in agreement with the existence of thrombin-induced PKC-dependent and independent pathways [5] . Therefore,
we have now identified C3G as the Rap1 GEF responsible for this Rap1 activation by PKC.
C3G transgenic mice showed an increase in neutrophils
As mentioned, we found no differences in the number of platelets between transgenic and control animals (Table 1) . However, haemocytometric analysis showed a significant increase in neutrophils in tgC3G mice as compared with control siblings (Table 2 ). This result was verified by flow cytometry using granulocyte specific markers Ly-6G/6C (Gr1) and CD11b (Mac1) (Fig. 7A, B) . In contrast, no significant effect was observed in C3GΔCat transgenic platelets. Moreover, no transgenic expression was detected in purified granulocytes obtained from hydrocortisone-driven bone marrow differentiation (data not shown), in agreement with the specific expression of the PF4 promoter in megakaryocytes/platelets.
Therefore, the increase in the percentage of neutrophils must be an indirect effect of the overexpression of C3G in platelets.
Discussion and conclusions
In this paper we demonstrate for the first time the involvement of C3G in platelet function. To do so, we have generated C3G transgenic mice in which the human C3G gene is under the megakaryocytic/platelet specific PF4 gene promoter. The backbone plasmid used in the generation of the transgenic constructs has been widely validated for its specific expression in megakaryocytes and platelets [24, 25, 31] . showing a lower response to agonists in C3GΔCat platelets, than in wild type platelets. This C3G DN transgene (C3GΔCat) has been previously demonstrated to act as a negative mutant in other systems [29, 32] . In all of our experimental approaches, the C3GΔCat mutant effect was opposite to that of the full C3G transgene. This clearly demonstrates that the effect of the C3G transgene is a direct effect on Rap1 and not a random or artefactual effect.
Results derived from blood clotting experiments demonstrate that C3G plays a relevant role in hemostasis. Hence, while control mice stop bleeding within the first 2 minutes, some of the C3GΔCat chimeras bled longer than 8 minutes, limit time of the experiment. In contrast, most C3G transgenic mice ceased bleeding within the first minute. These results are in agreement with the role of Rap1b in the regulation of the affinity state of integrin αIIbβ3 in mouse megakaryocytes and platelets [4, 33] . Furthermore, our results indicate that C3G
participates, at least, in thrombin, PMA, ADP and collagen-mediated platelet activation. In platelets, α-thrombin induces an early Rap1 activation, through a calcium-mediated pathway, independent of PKC activation. This is followed by a second activation phase mediated by PKC and, partially, by integrin αIIbβ3 [5, 34] .
So far, CalDAG-GEFI is the only Rap1 GEF with a proved role in platelet function [12] [13] [14] 35] . CalDAG-GEFI knockout mice are severely deficient in platelet aggregation in response to low thrombin and partially impaired in response to low PMA concentration.
However, CalDAG-GEFI knockout platelets are normally activated by high concentrations of these agonists (10X), and maintain a partial response to collagen, indicating the existence of CalDAG-GEF1-independent signaling pathways [12, 14, 36] . Here we show that, apart from CalDAG-GEFI, C3G is also endogenously expressed in platelets (see Fig. 2 ) and hence, it may play a physiological role. In fact, our results showing an increased response to thrombin in tgC3G platelets and an impaired response in tgC3GΔCat platelets, together with the opposite effects of both transgenes over thrombin-mediated Rap1 activation, indicate that C3G
participates in a thrombin-Rap1 pathway in platelets.
Additionally, based on our results showing an increase in PMA-induced activation of tgC3G platelets, together with the fact that platelet aggregation triggered by PMA is not impaired in CalDAG-GEF1 KO platelets [12] , it can be proposed a specific involvement of C3G in the second (PKC-dependent) phase of Rap1 activation induced by thrombin [5, 14] . This is further reinforced by results in Figure 6 showing that PKC-mediated Rap1 activation is mainly dependent on C3G. Hence, based on the results presented here and on with previous results showing the existence of CalDAG-GEFI and PKC independent pathways for Rap1 activation [14] , as well as participation of PKC in the second phase of thrombin-mediated Rap1 activation [5] , it is possible to propose a model where C3G could be a mediator in the thrombin-stimulated pathways in platelets ( Figure 8 ). We can not exclude the possibility that the increase in Rap1-GTP induced by thrombin in tgC3G platelets is, in part, a reflect of the higher basal Rap1-GTP levels in these platelets. However, the levels of Rap1-GTP in PMAstimulated tgC3G platelets are higher than the sum of basal Rap-GTP in tgC3G platelets and Rap1-GTP induced by PMA in wild type platelets (figure 6A), which suggests an amplification of the thrombin response and hence, the participation of C3G in this pathway. This is better reflected in Figure 6B , where all controls have been normalized, and is also evident in the thrombin activation studies ( Figure 4A-B) . In addition, other RapGEFs with detectable expression in mouse platelets [20] could contribute to PKC-dependent Rap1 activation, as there is still some platelet aggregation in transgenic C3GΔCat platelets stimulated with PMA.
ADP activates Rap1, both in human and mouse platelets [7] [8] [9] 34] . So, our results
showing an impaired response to ADP in tgC3GΔCat platelets indicate that C3G would mediate, at least in part, this ADP-induced Rap1 activation. We did not detect a significant ADP-induced activation of αIIbβ3 integrin with JON/A antibody (data not shown).
Nevertheless, ADP clearly activated fibrinogen-binding to αIIbβ3 integrin, which is in agreement with a synergistic effect between fibrinogen and ADP [37] . The observed increase in integrin activation in tgC3G platelets stimulated with thrombin, ADP or collagen was not due to an upregulation of αIIbβ3 gene expression induced by C3G, as we did not observe significant differences, either in total αIIbβ3 content (Fig. 2D) , or in that present on the surface (data not shown derived from cytometric analysis). Fibrinogen-binding and collagenmediated aggregation assays indicate that C3G participates in the inside-out activation of αIIbβ3 integrin. In addition, C3G contributes to collagen-mediated platelet activation probably through glycoprotein GPVI, the main collagen receptor that activates Rap1 in platelets [36, 38, 39] .
It is well known that Rap1 protein levels increase during megakaryocyte maturation [40] . On the other hand, C3G silencing in the megakaryoblastic cell line MEG-01 results in a decrease in total Rap1 protein content (data not shown). This result is in agreement with the propose role for C3G in the differentiation and maturation of megakaryocytes [3, 41, 42] .
Despite this putative role of C3G, we found no differences in platelet number between transgenic and wild type animals, although this result is in agreement with the phenotype observed in Rap1b-null mice [4] . One potential explanation would be the participation of C3G
in the initial steps of the megakaryopoiesis, but not in the final maturation to platelets.
Transgenic full-length C3G, but not C3GΔCat mice showed a significant increase in the number of neutrophils. As expected, purified neutrophils do not express transgenic C3G. This raises the possibility of an indirect effect of C3G overexpression in platelets, which could lead to the release of platelet-derived factors able to stimulate neutrophil development. It is known that platelets secrete chemokines that attract neutrophils and activate neutrophil production of pro-inflammatory cytokines [43] . For example, CXCL4 (PF4) can activate neutrophils in the presence of appropriate co-stimuli such as tumor necrosis factor alpha (TNF-α). Therefore, it is reasonable to hypothesize that C3G could stimulate the production and release of one or several platelet factors that stimulate neutrophil production. In support of this hypothesis resting C3G transgenic platelets displayed a low, but significant activation, as compared to control platelets (see Fig. 4 ).
Results from our group and others support the involvement of C3G in chronic myeloid leukemia (CML) [44] [45] [46] . CML chronic phase is characterized by the presence of a high percentage of mature neutrophils in peripheral blood, which present high levels of CrkL phosphorylation, a constitutive C3G adaptor protein [47] . Moreover, platelet functions such as aggregation and clot retraction are often abnormal in chronic myelogenous leukemia (CML) patients [48, 49] . CrkL is also abnormally phosphorylated in platelets from CML patients [50] , similarly to that observed in neutrophils. Interestingly, and in agreement with a putative role of C3G in neutrophils, Rap1a is activated by a variety of stimuli involved in neutrophil functions [51] . Rap1a interacts with neutrophil NADPH oxidase [52] and stimulates superoxide production during the oxidative burst [53] . Furthermore, another Rap1 GEF, CalDAG-GEFI, has also been shown to play an important role in neutrophil function [13, 35] . Based on that, our C3G transgenic models would be interesting tools in order to study, in a Bcr-Abl background, whether C3G plays a role in the initial steps of CML development by influencing abnormal neutrophil production and platelet function.
In conclusion, the work presented here shows for the first time that C3G plays a role in the regulation of platelet function and opens a new perspective on C3G as a potential therapeutic target in thrombotic disorders. Future studies will be conducted to determine whether C3G participates in inside-out or/and outside-in signaling and to dissect the specific signaling pathways that engage C3G in the regulation of Rap1 activity in platelets. Finally, the C3G transgenic mouse models will be useful to assess the potential role of C3G in neutrophil development and function as well as in CML development.
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